Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 20/20 | 1.00 |
| ▸ | ITGA4 | P13612 | 20/20 | 1.00 |
| ▸ | ITGB7 | P26010 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18589274 | 1.00 | ITGB1 (1.00) | ITGB1ITGA4ITGB7 | |
| SCHEMBL5164089 | 0.95 | ITGB1 (1.00) | ITGB1ITGA4ITGB7 | |
| SCHEMBL18068322 | 0.95 | ITGB1 (1.00) | ITGB1ITGA4ITGB7 | |
| SCHEMBL5162788 | 0.91 | ITGA4 (1.00) | ITGB1ITGA4ITGB7 | |
| SCHEMBL5159929 | 0.90 | ITGB1 (0.82) | ITGB1ITGA4ITGB7 | |
| SCHEMBL5162580 | 0.89 | ITGB1 (0.83) | ITGB1ITGA4ITGB7 | |
| SCHEMBL5159916 | 0.89 | ITGB1 (0.80) | ITGB1ITGA4ITGB7 | |
| SCHEMBL18607967 | 0.89 | ITGB1 (0.80) | ITGB1ITGA4ITGB7 | |
| SCHEMBL5163338 | 0.89 | ITGB1 (1.00) | ITGB1ITGA4ITGB7 | |
| SCHEMBL5162535 | 0.89 | ITGA4 (0.89) | ITGB1ITGA4ITGB7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1237878-B1 | 4-PYRIMIDINYL-N-ACYL-L-PHENYLALANINES | HOFFMANN LA ROCHE (CH) | 2007-03-21 | — | — | EP | claimed |
| EP-1237878-A2 | 4-PYRIMIDINYL-N-ACYL-L-PHENYLALANINES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-09-11 | — | — | EP | claimed |
| US-6380387-B1 | ANTIINFLAMMATORY AGENTS, ANTIASTHMATICS | HOFFMANN-LA ROCHE INC. | 2002-04-30 | — | — | US | claimed |
| WO-2001042225-A2 | 4-PYRIMIDINYL-N-ACYL-L-PHENYLALANINES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-06-14 | — | — | WO | claimed |
| US-11964987-B2 | Isoidide derivatives and methods of making and using same | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2024-04-23 | — | — | US | disclosed |
| US-20210002291-A1 | ISOIDIDE DERIVATIVES AND METHODS OF MAKING AND USING SAME | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2021-01-07 | — | — | US | disclosed |
| US-10815244-B2 | Isoidide derivatives and methods of making and using same | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2020-10-27 | — | — | US | disclosed |
| US-20170066778-A1 | SOLUBILITY FOR TARGET COMPOUNDS | Aunova Medchem LLC (US) | 2017-03-09 | — | — | US | disclosed |
| US-20170066778-A1 | SOLUBILITY FOR TARGET COMPOUNDS | Aunova Medchem LLC (US) | 2017-03-09 | — | — | US | disclosed |
| WO-2017040459-A1 | IMPROVED SOLUBILITY FOR TARGET COMPOUNDS | Aunova Medchem LLC (US) | 2017-03-09 | — | — | WO | disclosed |
| WO-2017040459-A1 | IMPROVED SOLUBILITY FOR TARGET COMPOUNDS | Aunova Medchem LLC (US) | 2017-03-09 | — | — | WO | disclosed |
| EP-1237878-B1 | 4-PYRIMIDINYL-N-ACYL-L-PHENYLALANINES | HOFFMANN LA ROCHE (CH) | 2007-03-21 | — | — | EP | disclosed |
| EP-1237878-B1 | 4-PYRIMIDINYL-N-ACYL-L-PHENYLALANINES | HOFFMANN LA ROCHE (CH) | 2007-03-21 | — | — | EP | disclosed |
| EP-1237878-A2 | 4-PYRIMIDINYL-N-ACYL-L-PHENYLALANINES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-09-11 | — | — | EP | disclosed |
| US-6380387-B1 | ANTIINFLAMMATORY AGENTS, ANTIASTHMATICS | HOFFMANN-LA ROCHE INC. | 2002-04-30 | — | — | US | disclosed |
| WO-2001042225-A2 | 4-PYRIMIDINYL-N-ACYL-L-PHENYLALANINES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11964987-B2 | Isoidide derivatives and methods of making and using same | MIF, ITGB7, ITGB4 | ITGB1 17/4885ITGA4 5/4885ITGB7 2/4885 |
| US-10815244-B2 | Isoidide derivatives and methods of making and using same | MIF, ITGB7, ITGB4 | ITGB1 17/4885ITGA4 5/4885ITGB7 2/4885 |
| US-20210002291-A1 | ISOIDIDE DERIVATIVES AND METHODS OF MAKING AND USING SAME | MIF, ITGB7, ITGB4 | ITGB1 17/4885ITGA4 5/4885ITGB7 2/4885 |
| US-20170066778-A1 | SOLUBILITY FOR TARGET COMPOUNDS | MIF, ITGB7, ITGB4 | ITGB1 10/4885ITGA4 4/4885ITGB7 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.